Search
NaviMed Pharma Biotech (00399.HK) Eyes Acquisition of Conflux Assets
2025-07-01 /
Read about 0 minute
Author：小编
On June 30, 2025, NaviMed Pharma Biotech revealed that it has entered into a memorandum of understanding with the seller and Conflux, with the intent to acquire the entire equity stake in the seller's Cayman Islands-registered wholly-owned subsidiary, contingent upon the seller successfully concluding the acquisition of Conflux assets. Conflux, a Hong Kong-based blockchain technology research and development company, is solely owned and managed by Executive Director Dr. Wu Ming. This potential acquisition seeks to bolster NaviMed Pharma Biotech's presence in the blockchain technology sector, facilitate entry into the digital innovation industry, diversify its business portfolio, and uncover new avenues for profit growth.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
